Introdução
O que você precisa saber de cara
Gliomatose cerebral é um padrão de crescimento raro de alguns tumores cerebrais, afetando pelo menos três lobos cerebrais, na maioria das vezes com envolvimento bilateral dos hemisférios cerebrais. Pode ser observada em alguns tipos de glioma difuso, mais notavelmente o glioblastoma. Consiste em filamentos infiltrativos que se espalham profundamente pelo cérebro, tornando-os muito difíceis de remover cirurgicamente ou de tratar com radioterapia e está associada a um prognóstico ruim.
Escala de raridade
<1/50kMuito rara
1/20kRara
1/10kPouco freq.
1/5kIncomum
1/2k
Encontrou um erro ou informação desatualizada? Sugira uma correção →
Entender a doença
Do básico ao detalhe, leia no seu ritmo
Preparando trilha educativa...
Sinais e sintomas
O que aparece no corpo e com que frequência cada sintoma acontece
Linha do tempo da pesquisa
Encontrou um erro ou informação desatualizada? Sugira uma correção →
Genética e causas
O que está alterado no DNA e como passa nas famílias
Nenhum gene associado encontrado
Os dados genéticos desta condição ainda estão sendo catalogados.
Diagnóstico
Os sinais que médicos procuram e os exames que confirmam
Tratamento e manejo
Remédios, cuidados de apoio e o que precisa acompanhar
Onde tratar no SUS
Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)
🇧🇷 Atendimento SUS — Gliomatose cerebral
Selecione um estado ou use sua localização para ver resultados.
Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.
Pesquisa ativa
Ensaios clínicos abertos e novidades científicas recentes
Ensaios em destaque
🟢 Recrutando agora
1 pesquisa recrutando participantes. Converse com seu médico sobre a possibilidade de participar.
Outros ensaios clínicos
14 ensaios clínicos encontrados, 1 ativos.
Publicações mais relevantes
Diffuse midline glioma, H3K27-altered: a rare presentation with gliomatosis cerebri growth pattern and progression toward midline.
A limited number of cases involving non-midline lesions have been documented in diffuse midline glioma (DMG), H3K27-altered, for which a definitive classification has yet to be developed. Additionally, no studies have investigated the temporal evolution of imaging features in diffuse non-midline gliomas. We herein report a case of DMG, H3K27-altered, initially presenting with a gliomatosis cerebri-like appearance, cystic lesions in the right frontal lobe, and progression toward the brainstem. Histopathological analysis and comprehensive genomic profiling indicated glioblastoma (GBM) or DMG, H3K27-altered. The patient was diagnosed with GBM because of imaging characteristics atypical for DMG; however, 9 months after the initial diagnosis, a pontine glioma emerged. This case indicates that DMG, H3K27-altered, may exhibit atypical characteristics, including non-midline cystic lesions, that can subsequently progress to pontine gliomas. Considering the limited therapeutic options available for this malignancy, the early recognition of such atypical presentations is crucial for achieving a timely and accurate diagnosis of DMG, H3K27-altered.
Pediatric H3 G34-mutant diffuse hemispheric glioma: clinical, imaging and molecular prognostic factors, MGMT expression, and temozolomide response.
Previous studies have demonstrated poor outcomes in pediatric patients with H3 G34-mutant diffuse hemispheric glioma (DHG). However, the biological basis for this therapeutic resistance remains poorly understood. Furthermore, the effectiveness of temozolomide (TMZ) and the role of surgery in pediatric patients remain uncertain. Therefore, we performed a multi-institutional retrospective analysis of the clinical, imaging, and molecular characteristics of 36 pediatric (≤ 18 years) patients with newly diagnosed H3 G34-mutant DHG. The median age of the cohort was 14 years (8-18 years). The median progression-free survival (PFS) was 0.7 years (95% CI 0.4-1.2 years), and the median overall survival (OS) was 1.8 years (95% CI 1.1-3.2 years). Gross total resection (GTR) was associated with improved PFS (p = 0.0046). Infiltration of three or more brain lobes (gliomatosis cerebri) was noted in 22.6% (7/31) of patients at presentation. Twenty-one patients (58.3%) received frontline TMZ and had improved PFS (p = 0.0049) compared to those who did not. Low MGMT expression was associated with better PFS (p = 0.0039) and better OS (p < 0.0001). In pediatric DHG, gene body/intronic CpG methylation, rather than promoter methylation, correlated with MGMT expression (p < 0.0001). MGMT promoter methylation was not significantly associated with PFS or OS. PDGFRA alterations (n = 13) were associated with inferior OS (p = 0.0035). Post-radiation local (± distant) recurrence occurred in 81.0% (17/21) of patients. Our findings reaffirm the dismal outcomes of pediatric H3 G34-mutant DHG, which exhibits radiation resistance, frequent widespread disease, and a novel mechanism of MGMT regulation. Our data support the use of frontline TMZ in pediatric patients and underscore the importance of GTR when feasible.
Evaluation of sex differences in survival among glioblastoma patients treated with immune checkpoint inhibitors.
Sex differences in glioblastoma (GBM) are recognized, but their treatment implications remain unclear. Recent preclinical studies have characterized mechanisms of sex-biased anti-tumor immunity in GBM, and have found in murine models that males derive greater survival benefit from immune checkpoint inhibitor (ICI). We evaluated sex differences associated with ICI in GBM patients. We retrospectively evaluated consecutive patients with newly diagnosed GBM (nGBM) or recurrent GBM (rGBM) treated with ICI on clinical trials at one institution from 2014 to 2022. Progression-free survival (PFS) and overall survival (OS) were evaluated by Kaplan-Meier analysis, univariate and multivariable regression models. Sex-by-treatment interactions were assessed relative to a concurrent reference group treated on non-ICI clinical trials. 296 patients with nGBM (58% male, 19% ICI) and 458 patients with rGBM (60% male, 40% ICI) were evaluated. In nGBM, ICI was not associated with sex difference in PFS (HRmale 1.35; 95% CI, 0.62-2.95; P = .446; P interaction = .142) or OS (HRmale 1.15 [0.53-2.53], P = .722; P interaction = .438) compared to non-ICI treatment. In rGBM, males receiving ICI had worse OS (HRmale 1.64 [1.09-2.47], P = .017) and trended towards worse PFS (HRmale 1.41 [0.94-2.11], P = .095), but sex differences with ICI were not significantly different compared to non-ICI treatment (PFS P interaction = .610; OS P interaction = .361). No sex differences were observed when all immunotherapies were analyzed collectively. In nGBM and rGBM, ICI therapy was not associated with sex difference in PFS or OS. Clinically meaningful sex-based outcome differences may be better understood by prospective evaluation in clinical trials.
Diffuse Pediatric High Grade Gliomas.
Advances in molecular and genomic testing have not only discriminated pediatric from adult high grade gliomas but also distinguished new entities in this family, 3 of which are new to the classification. We have reviewed the published literature to date and present the characteristic and most common findings of each type on structural MR imaging, as well as advanced imaging, where available. Prognostic features, particularly in diffuse midline gliomasK27a have also been described, in addition to practice recommendations.
Revisiting prognosis of oligodendroglioma patients in the 2021 WHO classification: incremental value of imaging features.
To investigate whether imaging factors can improve the prediction of progression-free survival (PFS) in patients with oligodendroglioma over clinicopathological features. A total of 180 patients diagnosed and treated for oligodendroglioma (IDH-mutant and 1p/19q codeleted) between 2005 and 2021 were included. Clinical data and preoperative MRI images were analyzed for qualitative and quantitative characteristics. Qualitative features included tumor location, calcification, gliomatosis cerebri pattern, cystic change, necrosis, and infiltrative pattern, while quantitative features included total, contrast-enhancing (CE), non-enhancing, and necrotic tumor volumes via automatic segmentation. Significant predictors of PFS were identified using univariable and multivariable Cox analyses. Two prognostic models were developed: model 1 (clinicopathological features) and model 2 (addition of imaging features). The prognostic value of the two models was compared. On univariable analysis, male sex, gliomatosis cerebri pattern, larger total tumor, CE tumor, and non-enhancing tumor volumes, and partial resection or biopsy were unfavorable predictors of PFS. On multivariable analysis, male sex (hazard ratio (HR) = 3.76, p = 0.012), larger CE tumor volume (HR = 1.06, p = 0.003) and partial resection or biopsy (HR = 6.83, p = 0.001) remained as unfavorable predictors for PFS. Compared with the clinicopathological model, the model adding imaging feature demonstrated a higher C-index (0.784 vs. 0.776) and iAUC (0.745 vs. 0.725), with a significantly high time-dependent AUC for PFS at 1 year (0.989 vs. 0.943, p = 0.001). The CE tumor volume on preoperative MRI is an independent prognostic factor in oligodendroglioma patients, potentially guiding follow-up and adjuvant treatment decisions. Question This study examines whether imaging factors can improve the prediction of progression-free survival (PFS) in patients with oligodendroglioma over clinicopathological features. Findings Larger contrast-enhancing (CE) tumor volume, male sex, and lesser resection independently predicted shorter PFS. Incorporating CE tumor volume improved model performance over clinicopathological features alone. Clinical relevance The clinicopathological and imaging features were comprehensively investigated in patients with oligodendroglioma to predict PFS. Incorporating CE tumor volume improved the model's predictive performance, providing valuable information for clinical decision-making in identifying high-risk patients.
Publicações recentes
Pediatric H3 G34-mutant diffuse hemispheric glioma: clinical, imaging and molecular prognostic factors, MGMT expression, and temozolomide response.
Diffuse Pediatric High Grade Gliomas.
Genomic determinants of the diffusely infiltrative gliomatosis cerebri phenotype.
Single-Voxel Proton Magnetic Resonance Spectroscopy Findings at 3 Tesla in a Dog With Gliomatosis Cerebri.
Revisiting pediatric HGGs and PNETs according to the WHO CNS5 criteria: A clinical and genomic retrospective analysis.
📚 EuropePMC341 artigos no totalmostrando 118
Pediatric H3 G34-mutant diffuse hemispheric glioma: clinical, imaging and molecular prognostic factors, MGMT expression, and temozolomide response.
Acta neuropathologicaEvaluation of sex differences in survival among glioblastoma patients treated with immune checkpoint inhibitors.
Neuro-oncology advancesDiffuse Pediatric High Grade Gliomas.
Neuroimaging clinics of North AmericaGenomic determinants of the diffusely infiltrative gliomatosis cerebri phenotype.
Journal of neuro-oncologySingle-Voxel Proton Magnetic Resonance Spectroscopy Findings at 3 Tesla in a Dog With Gliomatosis Cerebri.
Journal of veterinary internal medicineRevisiting pediatric HGGs and PNETs according to the WHO CNS5 criteria: A clinical and genomic retrospective analysis.
Neuro-oncology advancesDiffuse midline glioma, H3K27-altered: a rare presentation with gliomatosis cerebri growth pattern and progression toward midline.
Brain tumor pathologyRevisiting prognosis of oligodendroglioma patients in the 2021 WHO classification: incremental value of imaging features.
European radiologyDiffuse glioma with FGFR3::TACC3 gene fusion and prominent calcification: A case report.
Radiology case reportsGlioblastoma Mimicking Autoimmune Encephalitis.
The NeurohospitalistThe role of chemotherapy in patients with gliomatosis cerebri: a population-based study.
Neurosurgical reviewGliomatosis Cerebri Manifested as Parkinsonism Syndrome: A Case Report.
Case reports in neurological medicineDiffuse pediatric high-grade glioma of methylation-based RTK2A and RTK2B subclasses present distinct radiological and histomolecular features including Gliomatosis cerebri phenotype.
Acta neuropathologica communicationsPhysical therapy enhances physical and functional abilities in a female patient with gliomatosis cerebri.
Anales del sistema sanitario de NavarraRevisiting gliomatosis cerebri in adult-type diffuse gliomas: a comprehensive imaging, genomic and clinical analysis.
Acta neuropathologica communicationsComparative analysis of molecular and histological glioblastomas: insights into prognostic variance.
Journal of neuro-oncologyRevisiting oligodendroglioma grading in the 2021 WHO classification: calcification and larger contrast-enhancing tumor volume may predict higher oligodendroglioma grade.
NeuroradiologyGliomatosis cerebri in children: A poor prognostic phenotype of diffuse gliomas with a distinct molecular profile.
Neuro-oncologyRevisiting prognostic factors of gliomatosis cerebri in adult-type diffuse gliomas.
Journal of neuro-oncologyClinical and molecular study of radiation-induced gliomas.
Scientific reportsCase report: durable response of gliomatosis cerebri with concurrent tumor-treating fields (TTFields) and chemoradiotherapy treatment.
Chinese clinical oncologyGliomatosis cerebri (GC) growth pattern: A single-center analysis of clinical, histological, and molecular characteristics of GC and non-GC glioblastoma.
Neuro-oncology advances[Diffuse infiltrating primary cerebellar glioma involving the brainstem: a case report].
Rinsho shinkeigaku = Clinical neurologyA Novel Type of IDH-wildtype Glioma Characterized by Gliomatosis Cerebri-like Growth Pattern, TERT Promoter Mutation, and Distinct Epigenetic Profile.
The American journal of surgical pathologyThe Brain Tumor Segmentation (BraTS) Challenge 2023: Glioma Segmentation in Sub-Saharan Africa Patient Population (BraTS-Africa).
ArXivGliomatosis cerebri with blindness: A case report with literature review.
Radiology case reportsAn enduring debate on gliomatosis cerebri.
Brain tumor pathologyClinical characteristics and radiological features of glioblastoma, IDH-wildtype, grade 4 with histologically lower-grade gliomas.
Brain tumor pathologyClinical, Imaging and Neurogenetic Features of Patients with Gliomatosis Cerebri Referred to a Tertiary Neuro-Oncology Centre.
Journal of personalized medicineImaging features of localized IDH wild-type histologically diffuse astrocytomas: a single-institution case series.
Scientific reportsDoublecortin immunolabeling in canine gliomas with distinct degrees of tumor infiltration.
Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, IncMultifocal oligodendroglioma with callosal and brainstem involvement.
Surgical neurology internationalLeber's hereditary optic neuropathy with diffuse white matter changes mimicking gliomatosis cerebri: illustrative case.
Journal of neurosurgery. Case lessonsPediatric high-grade gliomas and the WHO CNS Tumor Classification-Perspectives of pediatric neuro-oncologists and neuropathologists in light of recent updates.
Neuro-oncology advancesGlioblastoma with Gliomatosis Cerebri Growth Pattern Presenting as Rapidly Progressive Dementia.
The NeurohospitalistT2/FLAIR Hyperintensity in Mesial Temporal Lobe: Challenging Differential Diagnosis.
Current medical imagingA rare case of gliomatosis cerebri lurking beneath the shadows of a stroke mimic.
Radiology case reportsMRI findings in a young dog with gliomatosis cerebri.
The Journal of small animal practiceNimotuzumab therapy in the treatment of pediatric central nervous system tumors: single-center experience.
Naunyn-Schmiedeberg's archives of pharmacologyGliomatosis Cerebri Growth Pattern: Association of Differential First-Line Treatment with Overall Survival in WHO Grade II and III Gliomas.
OncologyFluctuation of Clinical Signs With Near-Syncopal Episodes in a Dog With Gliomatosis Cerebri: A Diagnostic Challenge.
Topics in companion animal medicineCanine Gliomatosis Cerebri: Morphologic and Immunohistochemical Characterization Is Supportive of Glial Histogenesis.
Veterinary pathologyOutcomes of presumed malignant glioma treated without pathological confirmation: a retrospective, single-center analysis.
Neuro-oncology practiceA pediatric case of anaplastic astrocytoma with a gliomatosis cerebri; the growth pattern and changes in serum VEGF-121 levels after bevacizumab treatment.
Journal of clinical neuroscience : official journal of the Neurosurgical Society of AustralasiaPredictive factors for overall survival in surgical cases of gliomatosis cerebri from the National Cancer Database.
Journal of clinical neuroscience : official journal of the Neurosurgical Society of AustralasiaA phase I trial of lenalidomide and radiotherapy in children with diffuse intrinsic pontine gliomas or high-grade gliomas.
Journal of neuro-oncologyA case of pediatric gliomatosis cerebri harboring H3F3A K27 mutation.
Pediatric blood & cancerMultimodal neuroimaging of gliomatosis cerebri: a case series of four patients.
Acta radiologica openGliomatosis cerebri mimicking diffuse demyelinating disease: Case Report.
Radiology case reportsGliomatosis cerebri and Rasmussen's encephalitis: Two different entities causing refractory epilepsy. Comparison through two clinical cases.
Neuro-ChirurgieAdult H3K27M-mutant diffuse midline glioma with gliomatosis cerebri growth pattern: Case report and review of the literature.
International journal of surgery case reportsMortal consequences of a cooperative action between Takotsubo syndrome and increased intracranial pressure.
ESC heart failureGliomatosis cerebri (GC) or GC-like? A picture to be reconsidered in neuro-oncology based on large retrospective analysis of GC series.
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical NeurophysiologyImaging characteristics of adult H3 K27M-mutant gliomas.
Journal of neurosurgeryGliomatosis Cerebri: A Unique Presentation with Accompanying Clinical Nuance.
CureusAn autopsy case of widespread brain dissemination of glioblastoma unnoticed by magnetic resonance imaging after treatment with bevacizumab.
Surgical neurology internationalClinical relevance of molecular subgrouping of gliomatosis cerebri per 2016 WHO classification: a clinicopathological study of 89 cases.
Brain pathology (Zurich, Switzerland)Integrated diagnostics of diffuse astrocytic and oligodendroglial tumors.
Der PathologeAnalysis of preventability of malignancy-related maternal death from the nationwide registration system of maternal deaths in Japan.
The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal ObstetriciansCorticosteroid-induced immunodeficiency in a patient with gliomatosis cerebri: Are corticosteroids indicated in all brain tumors?
Clinical neuropathologyGliomatosis Cerebri Among Children and Adolescents: An Individual-Patient Data Meta-analysis of 182 Patients.
Journal of child neurology[Integrated diagnostics of diffuse astrocytic and oligodendroglial tumors. German version].
Der PathologeHeterogeneity of glioblastoma with gliomatosis cerebri growth pattern on diffusion and perfusion MRI.
Journal of neuro-oncologyRadiological Characteristics and Natural History of Adult IDH-Wildtype Astrocytomas with TERT Promoter Mutations.
NeurosurgeryPrognostic Factors and Survival of Gliomatosis Cerebri: A Systematic Review and Meta-Analysis.
World neurosurgeryClinical, neuroimaging and histopathological features of gliomatosis cerebri: a systematic review based on synthesis of published individual patient data.
Journal of neuro-oncologyWide Range of Clinical Outcomes in Patients with Gliomatosis Cerebri Growth Pattern: A Clinical, Radiographic, and Histopathologic Study.
The oncologistGliomatosis cerebri: a consensus summary report from the Second International Gliomatosis cerebri Group Meeting, June 22-23, 2017, Bethesda, USA.
Journal of neuro-oncologyLactoferrin- and RGD-comodified, temozolomide and vincristine-coloaded nanostructured lipid carriers for gliomatosis cerebri combination therapy.
International journal of nanomedicineIncidence and survival of gliomatosis cerebri: a population-based cancer registration study.
Journal of neuro-oncologyGliomatosis Cerebri: A Rare Brain Tumor.
Mymensingh medical journal : MMJAstroblastoma - reviewing literature and one case report.
Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologieA Pediatric Case of Diffuse Glioma Diagnosed at Autopsy.
Academic forensic pathologyMagnetic resonance imaging features of canine gliomatosis cerebri.
Veterinary radiology & ultrasound : the official journal of the American College of Veterinary Radiology and the International Veterinary Radiology Association2016 Updates to the WHO Brain Tumor Classification System: What the Radiologist Needs to Know.
Radiographics : a review publication of the Radiological Society of North America, IncNecrotic ulcerated and bleeding striae distensae following bevacizumab in a palliative setting for gliobastomatosis cerebri.
EcancermedicalsciencePositive influence of partial resection on overall survival of patients with overlapping glioblastomas.
Clinical neurology and neurosurgeryGliomatosis Cerebri: Current Understanding and Controversies.
Frontiers in oncologyWHO 2016 Classification of gliomas.
Neuropathology and applied neurobiologyGliomatosis cerebri: Prognosis based on current molecular markers.
Journal of clinical neuroscience : official journal of the Neurosurgical Society of AustralasiaAn Adolescent Presenting With Seizures as a Symptom of Gliomatosis Cerebri.
Pediatric emergency careGliomatosis cerebri in a 10-year-old male patient.
Asian journal of neurosurgeryPrevalence and clinicopathological features of H3.3 G34-mutant high-grade gliomas: a retrospective study of 411 consecutive glioma cases in a single institution.
Brain tumor pathologyMolecular alterations in pediatric gliomatosis cerebri are similar to those in less invasive forms of pediatric diffuse glioma.
Journal of neuro-oncologyNanoscale Functional Biomaterials for Cancer Theranostics.
Current medicinal chemistryManagement and Survival Patterns of Patients with Gliomatosis Cerebri: A SEER-Based Analysis.
World neurosurgeryBevacizumab for Patients with Recurrent Gliomas Presenting with a Gliomatosis Cerebri Growth Pattern.
International journal of molecular sciencesThe usefulness of 18F-fluorocholine PET/CT in the detection of recurrence of central nervous system primary neoplasms.
Revista espanola de medicina nuclear e imagen molecularFeline glioma: a retrospective study and review of the literature.
Journal of feline medicine and surgery[Gliomatosis Cerebri as a Clinical Entity].
Brain and nerve = Shinkei kenkyu no shinpoCanine spinal cord glioma.
Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, IncChanges in cerebral metabolism during ketogenic diet in patients with primary brain tumors: 1H-MRS study.
Journal of neuro-oncologyPerioperative Risk Assessment of Patients with Gliomatosis Cerebri.
World neurosurgeryGliomatosis cerebri: A consensus summary report from the First International Gliomatosis cerebri Group Meeting, March 26-27, 2015, Paris, France.
Pediatric blood & cancerAntigen-specific immunoreactivity and clinical outcome following vaccination with glioma-associated antigen peptides in children with recurrent high-grade gliomas: results of a pilot study.
Journal of neuro-oncologyRadiology Case of the Month: Gliomatosis Cerebri.
The Journal of the Louisiana State Medical Society : official organ of the Louisiana State Medical SocietyGliomatosis Cerebri in the Brain of a Cat.
Veterinary sciencesNanostructured lipid carriers, solid lipid nanoparticles, and polymeric nanoparticles: which kind of drug delivery system is better for glioblastoma chemotherapy?
Drug deliveryEpidermal Growth Factor Receptor and Ki-67 Expression in Canine Gliomas.
Veterinary pathologyMSI detection and its pitfalls in CMMRD syndrome in a family with a bi-allelic MLH1 mutation.
Familial cancerAdvanced Imaging for Biopsy Guidance in Primary Brain Tumors.
CureusPediatric gliomatosis cerebri mimicking tubercular encephalitis.
Journal of pediatric neurosciencesGliomatosis cerebri: Case series of six cases with review of literature.
Journal of neurosciences in rural practiceGliomatosis cerebri in children shares molecular characteristics with other pediatric gliomas.
Acta neuropathologicaMalignant transformation of diffuse infiltrating glial neoplasm after prolonged stable period initially discovered with hypothalamic hamartoma.
Neurologia i neurochirurgia polskaGliomatosis cerebri: no evidence for a separate brain tumor entity.
Acta neuropathologicaEpilepsy surgery related to pediatric brain tumors: Miami Children's Hospital experience.
Journal of neurosurgery. PediatricsGliomatosis cerebri with spinal metastasis presenting with chronic meningitis in two boys.
Journal of the Formosan Medical Association = Taiwan yi zhiPediatric Gliomatosis Cerebri: A Review of 15 Years.
Journal of child neurologyVincristine and temozolomide combined chemotherapy for the treatment of glioma: a comparison of solid lipid nanoparticles and nanostructured lipid carriers for dual drugs delivery.
Drug deliveryNovel RGD containing, temozolomide-loading nanostructured lipid carriers for glioblastoma multiforme chemotherapy.
Drug delivery"Fungimitosis": Invasive fulminant Aspergillus brain infection mimicking gliomatosis cerebri.
Neurology IndiaNanostructured lipid carriers based temozolomide and gene co-encapsulated nanomedicine for gliomatosis cerebri combination therapy.
Drug deliveryGliomatosis cerebri in L-2-hydroxyglutaric aciduria.
Acta neurologica BelgicaCorticosteroid sensitivity in gliomatosis cerebri delays diagnosis.
Practical neurologyGliomatosis cerebri in a 12-year-old patient.
Pediatric neurologyGliomatosis cerebri mimicking encephalitis evaluated using fluorine-18 fluorodeoxyglucose: Positron emission tomography/computed tomography.
Indian journal of nuclear medicine : IJNM : the official journal of the Society of Nuclear Medicine, IndiaGliomatosis cerebri having a poor performance status without recurrence after radiotherapy: a single institutional experience.
Clinical neurology and neurosurgeryAssociações
Organizações que acompanham esta doença — pra ter apoio e orientação
Ainda não temos associações cadastradas para Gliomatose cerebral.
É de uma associação que acompanha esta doença? Fale com a gente →
Comunidades
Grupos ativos de quem convive com esta doença aqui no Raras
Ainda não existe comunidade no Raras para Gliomatose cerebral
Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.
Tire suas dúvidas
Perguntas, dicas e experiências compartilhadas aqui na página
Participe da discussão
Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.
Fazer loginDoenças relacionadas
Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico
Ainda não achamos doenças com sintomas parecidos o suficiente.
Referências e fontes
Bases de dados externas citadas neste artigo
Publicações científicas
Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.
- Diffuse midline glioma, H3K27-altered: a rare presentation with gliomatosis cerebri growth pattern and progression toward midline.
- Pediatric H3 G34-mutant diffuse hemispheric glioma: clinical, imaging and molecular prognostic factors, MGMT expression, and temozolomide response.
- Evaluation of sex differences in survival among glioblastoma patients treated with immune checkpoint inhibitors.
- Diffuse Pediatric High Grade Gliomas.
- Revisiting prognosis of oligodendroglioma patients in the 2021 WHO classification: incremental value of imaging features.
- Genomic determinants of the diffusely infiltrative gliomatosis cerebri phenotype.
- Single-Voxel Proton Magnetic Resonance Spectroscopy Findings at 3 Tesla in a Dog With Gliomatosis Cerebri.
- Revisiting pediatric HGGs and PNETs according to the WHO CNS5 criteria: A clinical and genomic retrospective analysis.
Bases de dados e fontes oficiais
Identificadores e referências canônicas usadas para montar este verbete.
- ORPHA:251582(Orphanet)
- MONDO:0016683(MONDO)
- GARD:6514(GARD (NIH))
- Busca completa no PubMed(PubMed)
- Q1531482(Wikidata)
Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.
Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar
